Passage Bio announced a strategic review and a plan to cut 75% of its workforce after an FDA Type C meeting challenged the design for its lead gene therapy PBFT02 in frontotemporal dementia with granulin mutations (FTD-GRN). Passage said the FDA did not support a single-arm registrational trial design and instead required a randomized controlled trial. The company said it expects the workforce reduction to be completed mostly in the second and third quarters, with projected severance and exit costs of about $3.3 million. Passage also disclosed it had cash and cash equivalents of $46.3 million as of Dec. 31 and expected funding into Q1 2027. Passage reported earlier that ongoing Phase 1/2 upliFT-D data suggest PBFT02 may slow neurodegeneration, with improvements in brain atrophy and plasma neurofilament biomarkers and durable progranulin elevations, while evaluating dosing approach updates.